Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Semorinemab in Healthy Volunteers and Alzheimer's Disease
NCT02820896Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semorinemab in Alzheimer's disease (AD) (5 arms), sponsored by Genentech. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Dose Limiting Adverse Events and 1 more. Started Jun 2016; status: completed.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02820896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820896.